Basilea Pharmaceutica (LTS:0QNA) Total Stockholders Equity : CHF-10.0 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Basilea Pharmaceutica Total Stockholders Equity?

Basilea Pharmaceutica's Total Stockholders Equity for the quarter that ended in Dec. 2023 was CHF-10.0 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Basilea Pharmaceutica's Book Value per Share for the quarter that ended in Dec. 2023 was CHF-0.83. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Basilea Pharmaceutica's Debt-to-Equity for the quarter that ended in Dec. 2023 was -12.86.

Basilea Pharmaceutica Total Stockholders Equity Historical Data

The historical data trend for Basilea Pharmaceutica's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Total Stockholders Equity Chart

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

-92.96

-102.05

-58.61

-20.71

-10.00

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															-58.61	-67.17	-20.71	14.99	-10.00

Basilea Pharmaceutica (LTS:0QNA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Basilea Pharmaceutica's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-10.002	-	0)	/	12.0017
	=	-0.83

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Basilea Pharmaceutica's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.515	+	111.091)	/	-10.002
	=	-12.86

Basilea Pharmaceutica Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (LTS:0QNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (LTS:0QNA) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

BSLNz:UK BSLN:Switzerland

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (LTS:0QNA) Headlines

No Headlines